PatientsVille.com Logo


Formula Medical Research Studies

Up-to-date List of Formula Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Formula Medical Research Studies

Rank Status Study
1 Recruiting Generic Formulations of Commonly-used Oral Drugs in Saudi Arabia:Interchangeability & Post-marketing Quality
Conditions: Generic Drug Quality;   Generic Formulation Interchangeability
Intervention: Drug: one of the 15 drugs listed below
Outcome Measures: bioequivalence;   Intra-subject variation despite average bioequivalence
2 Unknown  Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia
Condition: Hypoglycemia
Interventions: Drug: glucagon;   Drug: low dose experimental Formulation;   Drug: high dose experimental Formulation;   Drug: Medium dose experimental glucagon Formulation
Outcome Measures: Percentage of responders;   Number of subjects with adverse events;   Area under the serum concentration versus time curve (AUC) of glucagon;   Peak serum concentration (Cmax)of glucagon;   Peak plasma concentration (Cmax) of glucose;   Area under the plasma concentration versus time curve (AUC) of glucose
3 Unknown  Comparative Bioavailability Study of an Immediate Release and Controlled Release Oral Formulations of Huperzine A
Conditions: Healthy;   Bioavailability
Intervention: Drug: Huperzine A
Outcome Measures: Pharmacokinetic parameters of Huperzine A different Formulations;   Laboratory testing of peripheral AchE inhibition by Huperzine A. Evaluation of adverse events. Laboratory testing of peripheral AchE inhibition by Huperzine A. Evaluation of adverse events.
4 Recruiting Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73
Condition: Staphylococcal Infection
Interventions: Drug: XF-73 in 4% Klucel® gel;   Drug: XF-73 in 2% Klucel® gel;   Other: Placebo in 4% Klucel® gel
Outcome Measures: The local (nasal and nasal passage) and systemic safety and tolerability of XF-73 following nasal administration in healthy male and female subjects via adverse events, physical exams, nasal exams, vital signs, clinical lab tests and electrocardiograms.;   The efficacy of the modified Formulation of XF-73 and of the previous Formulation on nasal load of S. aureus after daily treatment with XF-73 for five days as compared to placebo (in Part 2 of the study only).;   The pharmacokinetics (PK) of XF-73 following nasal administration of two concentrations of a modified Formulation (in both parts of the study) and a single concentration of a previously investigated Formulation (in Part 2 of the study).
5 Recruiting Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: Drug: Triptolide-Containing Formulation;   Drug: Placebo
Outcome Measures: renal volume measured by high resolution magnetic resolution imaging;   Estimated glomerular filtration rate (eGFR);   Adverse events.
6 Recruiting Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability.
Conditions: Advanced Solid Malignancy,;   Safety and Tolerability,;   Pharmacokinetics, Pharmacodynamics,;   Tumour Response,
Intervention: Drug: AZD5363
Outcome Measures: Part A: AZD5363 PK (plasma concentration) of tablet and capsule Formulations;   Part B: PK (plasma concentration) of a AZD5363 tablet Formulation with food;   Part A: PK for AZD5363 new tablet Formulation (maximum plasma concentration at steady state);   Part B: Within-patient comparison of steady state exposure of AZD5363 tablet with/without food (plasma concentrations Css max and Css min);   Part A and B: Safety and tolerability of AZD5363 in terms of adverse events;   Parts A,B: Obtaining of a preliminary assessment of anti-tumour activity of AZD5363 via use of Response Evaluation Criteria in Sold Tumours (RECIST) version;   Part B: Safety and tolerability of AZD5363 tablet in terms of adverse events and serious adverse events, death, changes from baseline of laboratory data (clinical chemistry, haematology, urinalysis), vital signs, and electrocardiogram (ECG) parameters;   Part A: PK for AZD5363 new tablet Formulation (time to Cmax);   Part A: PK for AZD5363 new tablet Formulation (area under plasma concentration time curve at steady state);   Part A: PK for AZD5363 new tablet Formulation (oral plasma clearance at steady state);   Part B: Within-patient comparison of steady state exposure of AZD5363 tablet with/ without food (time to Css max);   Part B: Within-patient comparison of steady state exposure of AZD5363 tablet with/without food (area under the plasma concentration-time curve at steady state);   Part A and B: Safety and tolerability of AZD5363 in terms of death;   Part A and B: Safety and tolerability of AZD5363 in terms of changes from baseline of laboratory data;   Part A and B: Safety and tolerability of AZD5363 in terms of changes in electrocardiogram (ECG) parameters
7 Recruiting A Crossover Study to Evaluate Relative Bioavailability of Two JNJ-54781532 Tablet Formulations in Healthy Adult Participants
Condition: Healthy
Interventions: Drug: Formulation 2;   Drug: Formulation 1
Outcome Measures: Maximum Plasma Concentration (Cmax) of JNJ-54781532;   Time to Reach Maximum Concentration (tmax) of JNJ-54781532;   Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time (AUC [0-last]) of JNJ-54781532;   Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) of JNJ-54781532;   Relative Bioavailability of JNJ-54781532;   Time to last quantifiable plasma concentration (tlast) of JNJ-54781532;   Area Under the Plasma Concentration Percentage (%) Extrapolation of JNJ-54781532;   Elimination Half-Life (t [1/2] Lambda) of JNJ-54781532;   Rate Constant (Lambda[z]);   Adjusted Coefficient of Determination (R^2 adj)
8 Recruiting A Study to Compare How Tamsulosin is Absorbed to the Body After Administration of Two Types of Tamsulosin Formulation Under Fed and Fasted Conditions in Chinese Healthy Subjects
Conditions: Healthy;   Pharmacokinetics of Tamsulosin Hydrochloride
Interventions: Drug: Tamsulosin Formulation-A;   Drug: Tamsulosin Formulation-B
Outcome Measures: Pharmacokinetic parameter of tamsulosin (AUC0-t);   Pharmacokinetic parameter of tamsulosin (Cmax);   Pharmacokinetic parameter of tamsulosin (AUC0-∞);   Pharmacokinetic parameter of tamsulosin (Tmax);   Pharmacokinetic parameter of tamsulosin (T1/2);   Safety evaluated by physical examinations, vital signs, electrocardiograms, laboratory assessments, and adverse events.
9 Recruiting Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension
Conditions: Open-Angle Glaucoma;   Ocular Hypertension
Interventions: Drug: bimatoprost ophthalmic Formulation A;   Drug: bimatoprost ophthalmic Formulation B;   Drug: bimatoprost ophthalmic Formulation C;   Drug: bimatoprost ophthalmic Formulation D;   Drug: bimatoprost ophthalmic Formulation E;   Drug: bimatoprost ophthalmic Formulation F;   Drug: Sham;   Drug: timolol 0.5%;   Drug: bimatoprost ophthalmic solution 0.03%;   Drug: latanoprost 0.005%;   Drug: timolol vehicle (placebo)
Outcome Measures: Stage 1: Change from Baseline in Intraocular Pressure (IOP);   Stage 2: Change from Baseline in IOP;   Stage 2: IOP;   Time to Escape Treatment;   Time to Second Injection
10 Recruiting Comparison of Two Formulations of Proellex for Oral Administration
Condition: Healthy
Interventions: Drug: Telapristone Acetate, Proellex 12 mg Formulation A;   Drug: Telapristone Acetate, Proellex 12 mg Formulation B
Outcome Measures: Pharmacokinetic Comparison;   Dose Formulation safety
11 Recruiting A Study Investigating the Bioavailability of a High Concentration Liquid Formulation Versus a Reference Lyophilized Formulation of Gantenerumab in Healthy Volunteers
Condition: Healthy Volunteer
Intervention: Drug: gantenerumab
Outcome Measures: Plasma concentration of gantenerumab;   Incidence of adverse events
12 Recruiting A Study of Whether 2 New Oral Formulations of a Strong Pain Killer Release the Same Amount of Drug Into the Body as the Marketed Medication
Condition: Pain
Interventions: Drug: Active comparator MR2XXX;   Drug: MRXXX;   Drug: MR1XXX;   Drug: MRXXX and MR1XXX
Outcome Measures: Assess the pharmacokinetics and potential for bioequivalence of two novel Formulations;   The primary objective of the definitive phase is to assess bioequivalence of one or two experimental capsule Formulations;   Assess the safety and tolerability of two experimental Formulations of Tablet and Capsule in a fasted and fed state by the collection of adverse events, vital signs, clinical laboratory results and ECGs
13 Recruiting Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of the Topical Formulation SB011 Applied to Lesional Skin in Patients With Atopic Eczema
Condition: Mild to Moderate Atopic Dermatitis
Interventions: Drug: SB011, 2 % (Water/Oil/Water) emulsion of hgd40;   Drug: Multiple W/O/W Formulation, active ingredient-free vehicle
Outcome Measures: Change of local SCORing atopic dermatitis (SCORAD) from baseline to Day 15.;   The change from baseline in modified local SCORAD;   Modified local SCORAD;   Change from baseline in transepidermal water loss (TEWL);   TEWL on Days 1, 3, 5, 8, 12, and 15;   Subjective assessment of pruritus using a 10-point rating scale;   Subjective efficacy assessment on Days 3, 5, 8, 12 and 15;   Subjective dermal tolerability assessment using a 5-point rating scale on Days 3, 5, 8, 12 and 15;   Pharmacokinetic outcome measure;   Physical examination of the skin and Vital signs;   Adverse Events;   Standard Safety laboratory
14 Recruiting Phase1 Study of Gemcitabine HCl Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas
Conditions: Advanced Solid Malignancies;   Malignant Lymphomas
Intervention: Drug: Gemcitabine HCl Oral Formulation
Outcome Measures: To determine MTD and DLT of Gemcitabine Oral Formulation;   Safety;   characterize the PK of D07001-F4;   ORR(Objective Response Rate) and tumor response
15 Unknown  Efficacy and Safety of Curcumin Formulation in Alzheimer's Disease
Condition: Alzheimer Disease
Interventions: Dietary Supplement: Curcumin Formulation;   Dietary Supplement: Placebo
Outcome Measures: To determine if curcumin Formulation affects mental capacity in Alzheimer's patients based on mental exams;   To determine if curcumin Formulation changes blood concentrations of amyloid-beta
16 Not yet recruiting Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
Conditions: Attention-deficit/Hyperactivity Disorder;   Autism Spectrum Disorder
Intervention: Drug: Methylphenidate extended-release liquid Formulation
Outcome Measure: Adult ADHD Investigator Symptom Report Scale (AISRS)
17 Recruiting Study on Two Different Formulations of 6-mercaptopurine. Tablet Versus Oral Liquid
Conditions: Acute Lymphoblastic Leukemia;   6-mercaptopurine Therapy
Interventions: Drug: Xaluprine;   Drug: Puri-Nethol
Outcome Measures: Time to maximum concentration (Tmax);   Area under curve(AUC);   Maximum concentration (Cmax);   Time to half-life (T½)
18 Not yet recruiting Study to Evaluate the PK, Relative Bioavailability and Safety of TG-2349 With Single Oral Dose Under Fed Condition in Healthy Volunteers
Condition: Healthy
Interventions: Drug: TG-2349 as the original Formulation;   Drug: TG-2349 as a new capsule Formulation
Outcome Measures: Primary pharmacokinetic parameters: AUC0-t, AUC0-inf and Cmax;   Secondary pharmacokinetic parameters:Tmax, t1/2, CL/F, V/F and λz;   Urine pharmacokinetic parameters: Urine Ae%;   Stool pharmacokinetic parameters: Stool Ae%;   Safety parameters: Incidence and severity of AEs, changes from baseline in safety laboratory values, 12-lead ECG parameters, vital signs, and physical examination.
19 Recruiting Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer
Interventions: Dietary Supplement: Chinese herbal Formulation PHY906;   Drug: sorafenib tosylate;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: Recommended phase II dose, determined according to incidence of dose-limiting toxicity (DLT) graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4;   Adverse events as determined by NCI CTCAE version 4;   Serious adverse events as determined by NCI CTCAE version 4;   Discontinuation rate;   Dose adjustment rate;   Tumor response in terms of best overall response, assessed using RECIST;   Sorafenib tosylate concentration after co-administration with Chinese herbal Formulation PHY906
20 Not yet recruiting Sensitivity of Pharmacokinetics to Differences in Aerodynamic Particle Size Distribution
Condition: Asthma
Interventions: Drug: Fluticasone Propionate Formulation 1;   Drug: Fluticasone Propionate Formulation 2;   Drug: Fluticasone Propionate Formulation 3;   Drug: Fluticasone Propionate Formulation 3*
Outcome Measures: Area Under the Plasma Concentration versus time curve (AUC) for Drug Fluticasone Propionate;   Peak plasma concentration for fluticasone propionate

These studies may lead to new treatments and are adding insight into Formula etiology and treatment.

A major focus of Formula research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Formula